Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Next Previous
X
Search
Trial Profile

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Tabelecleucel (Primary)
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Atara Biotherapeutics

    • Most Recent Events

    • 04 Jun 2024 Results assessing safety outcomes (n=12; As of the final data cutoff) subjects treated with tabelecleucel with pembrolizumab in recurrent/metastatic Epstein Barr virus-associated nasopharyngeal carcinoma in the phase 1b portion of the study, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Sep 2022 Status changed from completed to discontinued.
    • 21 Sep 2021 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top